GLP-1 Pills for Weight Loss are Here
Always use a fresh, sterile needle for every injection and dispose of it immediately in a sharps container never recap it
Clinical Data Clinical Trial Results 28.7% Average Weight Loss 68 weeks 58.6% Achieved 25%+ Loss of participants 445 Trial Participants Phase 3 Data from the Phase 3 TRIUMPH-4 trial of retatrutide, reported by Eli Lilly (topline, 2025)
What this means for researchers now The practical takeaway is this: semaglutide is the known quantity, retatrutide is the exciting frontier, and the field will continue evolving rapidly regardless of which compound someone chooses today
Whilst the UK advises that women using GLP-1 receptor agonists should avoid pregnancy and use effective contraception, this advice is not being followed consistently in Australian clinical practice, says Associate Professor Luke Grzeskowiak
At Genesis II, we are seeing an influx of clients asking the same question: Is my medication making my hair shed